Evidence map›Paper›PMID 42113378›Full record

ArticleAnnals of surgical oncology2026

Superiority of [

Xiaolin Chen, Mengjiao Wang, Yan Zhao, Xiao Pang, Ruoxi Yang, Fenglian Jing, Yunuan Liu, Meng Dai, Yuhan Sun, Qiang Fu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaolin Chen *Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Mengjiao Wang *Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yan Zhao *Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xiao PangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Ruoxi YangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Fenglian JingDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yunuan LiuDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Meng DaiDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yuhan SunDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Qiang FuDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xiaoshan ChenDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. 22032100140@stu.hebmu.edu.cn.
Xinming ZhaoDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. xinmingzhao@hebmu.edu.cn.ORCID http://orcid.org/0000-0002-7060-2643

Funding

Medical Science Research Project of Hebei Grant No. 20230917Natural Science Foundation of Hebei Province H2024206154the Foundation of the Hebei Provincial Department of Education Degree Office Graduate Innovation Funding Project for Higher Education Institutions No. CXZZBS2025108
6 · The paper itself

Abstract

backgroundThis study aimed to investigate the diagnostic value of [gallium-68]-labeled fibroblast activation protein inhibitor ([

methodsThe study enrolled patients with suspected peritoneal malignancy. [

resultsIn this study, 261 patients underwent [

conclusions[

Indexed as

Fluorodeoxyglucose F18Gallium RadioisotopesMagnetic Resonance ImagingPeritoneal NeoplasmsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedAged, 80 and overContrast MediaEndopeptidasesFemaleFibroblast Activation Protein AlphaFollow-Up StudiesHumansMale68Ga-FAPIContrast MediaEndopeptidasesFibroblast Activation Protein AlphaFluorodeoxyglucose F18Gallium RadioisotopesQuinolinesRadiopharmaceuticals[18F]-FDG PET/CT[68Ga]Ga-FAPI-04Contrast-enhanced CTMagnetic resonance imagingPeritoneal carcinomatosis

Identifiers

PMID42113378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.